ascopubs.org

Development of custom amplicon-based test systems for detecting KRAS, NRAS, and BRAF gene mutations in colorectal cancer using next-generation sequencing (NGS).

Correlating survival outcomes in patients with advanced prostate cancer with novel hyperpolarized 13C MRI metabolic imaging biomarkers. KRAS c.436G > A p.Ala146Thr ...
Nasdaq

QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration ...
Business Wire

GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%

Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
ascopubs.org

Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
Medscape

Most Cost-effective to Use Immunotherapy First in Melanoma

Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.
FiercePharma

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
Medscape

The Diagnostic Role and Clinical Relevance of Determination of BRAF Status in Brain Tumors

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
Nasdaq

FDA OKs Guardant360 CDx As Companion Test For BRAF V600E Metastatic Colorectal Cancer

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
The American Journal of Managed Care

FDA Approves First CGP Test as Companion Diagnostic for BRAF Inhibitor Therapies for Melanoma

The FDA approved FoundationOneCDx as the first companion diagnostic for current and future BRAF inhibitor therapeutics used to treat melanoma, including both monotherapies and combination therapies.
Yahoo

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
FierceBiotech

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...